Compass Therapeutics Inc.

Stock Chart, Company Information, and Scan Results

$3.44(as of Sep 5, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Compass Therapeutics Inc. Company Information, Fundamentals, and Technical Indicators

Stock Price$3.44
Ticker SymbolCMPX
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees35
CountyUSA
Market Cap$590.2M
EBIDTA-67.3M
10-Day Moving Average3.31
P/E Ratio-7.67
20-Day Moving Average3.12
Forward P/E Ratio0.00
50-Day Moving Average2.99
Earnings per Share-0.45
200-Day Moving Average2.38
Profit Margin-Infinity%
RSI62.85
Shares Outstanding171.6M
ATR0.20
52-Week High4.08
Volume388,871
52-Week Low1.27
Most Recent Support Level3.29
Book Value93.2M
Most Recent Resistance Level3.52
P/B Ratio5.10
Upper Keltner3.57
P/S RatioInfinity
Lower Keltner2.67
Debt-to-Equity Ratio3.57
Next Earnings Date11/06/2025
Cash Surplus9.0M
Next Ex-Dividend DateUnknown

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.

Compass Therapeutics Inc. In Our Stock Scanner

As of Sep 08, 2025
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Heikin Ashi BreakoutScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cup and HandleScan Type: Chart Pattern Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.